Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$1.7 billion.

  • Ptc Therapeutics' Enterprise Value fell 6655.7% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year decrease of 6655.7%. This contributed to the annual value of -$1.1 billion for FY2024, which is 2999.26% down from last year.
  • Per Ptc Therapeutics' latest filing, its Enterprise Value stood at -$1.7 billion for Q3 2025, which was down 6655.7% from -$2.0 billion recorded in Q2 2025.
  • Ptc Therapeutics' 5-year Enterprise Value high stood at -$286.3 million for Q1 2023, and its period low was -$2.0 billion during Q1 2025.
  • Moreover, its 5-year median value for Enterprise Value was -$876.7 million (2023), whereas its average is -$894.8 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 6676.83% in 2022, then crashed by 24373.22% in 2024.
  • Ptc Therapeutics' Enterprise Value (Quarter) stood at -$773.4 million in 2021, then soared by 46.89% to -$410.7 million in 2022, then tumbled by 113.47% to -$876.7 million in 2023, then dropped by 29.99% to -$1.1 billion in 2024, then tumbled by 48.09% to -$1.7 billion in 2025.
  • Its Enterprise Value was -$1.7 billion in Q3 2025, compared to -$2.0 billion in Q2 2025 and -$2.0 billion in Q1 2025.